<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ishiguro K</submitter><funding>NICHD NIH HHS</funding><pagination>117-124</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4827869</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2(2)</volume><pubmed_abstract>Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines is valuable for development of therapeutic strategies to avoid platinum inefficacy and to exploit platinum sensitivity. TOV-21G devoid of FANCF expression, OV-90 and SKOV-3 were employed as examples of platinum-sensitive, platinum-intermediate and platinum-resistant cell lines, respectively. Antineoplastic agents examined included mitomycin C, doxorubicin, etoposide, gemcitabine, chlorambucil, paclitaxel, triapine and X-rays. Their effectiveness against cell lines was analyzed by clonogenic assays. Cytotoxic profiles of mitomy</pubmed_abstract><journal>Journal of translational science</journal><pubmed_title>Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.</pubmed_title><pmcid>PMC4827869</pmcid><funding_grant_id>K12 HD047018</funding_grant_id><pubmed_authors>Ishiguro K</pubmed_authors><pubmed_authors>Baumann RP</pubmed_authors><pubmed_authors>Ratner ES</pubmed_authors><pubmed_authors>Sartorelli AC</pubmed_authors><pubmed_authors>Rutherford TJ</pubmed_authors><pubmed_authors>Penketh PG</pubmed_authors><pubmed_authors>Zhu R</pubmed_authors><pubmed_authors>Zhu YL</pubmed_authors><pubmed_authors>Lin ZP</pubmed_authors><pubmed_authors>Shyam K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.</name><description>Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines is valuable for development of therapeutic strategies to avoid platinum inefficacy and to exploit platinum sensitivity. TOV-21G devoid of FANCF expression, OV-90 and SKOV-3 were employed as examples of platinum-sensitive, platinum-intermediate and platinum-resistant cell lines, respectively. Antineoplastic agents examined included mitomycin C, doxorubicin, etoposide, gemcitabine, chlorambucil, paclitaxel, triapine and X-rays. Their effectiveness against cell lines was analyzed by clonogenic assays. Cytotoxic profiles of mitomy</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016</publication><modification>2025-06-01T12:01:57.689Z</modification><creation>2019-06-06T15:41:42Z</creation></dates><accession>S-EPMC4827869</accession><cross_references><pubmed>27076919</pubmed><doi>10.15761/JTS.1000127</doi><doi>10.15761/jts.1000127</doi></cross_references></HashMap>